SEC Comment Letter for Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704) (CLRB) — Jan 20, 2011

Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)
Date: Jan. 20, 2011 · CIK: 0001279704 · Accession: 0000000000-11-003953

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-119366

Date

January 20, 2011

Author

Jeffrey Riedler

Form

UPLOAD

Company

Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)

Letter

Re: Novelos Therapeutics, Inc. Form 10-K Filed March 30, 2010 File No. 333-119366 Dear Mr. Palmin: We have completed our review of your fili ngs and do not have any further comments at this time. Sincerely,

January 20, 2011

Harry S. Palmin President and Chief Executive Officer Novelos Therapeutics, Inc. One Gateway Center, Suite 504 Newton, Massachusetts 02458

Jeffrey Riedler Assistant Director

Show Raw Text

January 20, 2011

Harry S. Palmin President and Chief Executive Officer Novelos Therapeutics, Inc. One Gateway Center, Suite 504
Newton, Massachusetts 02458

Re: Novelos Therapeutics, Inc.  Form 10-K
Filed March 30, 2010 File No. 333-119366
 Dear Mr. Palmin:
 We have completed our review of your fili ngs and do not have any further comments at
this time.
Sincerely,

Jeffrey Riedler Assistant Director

SecProbe.io